Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio.

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema. This article aims to discuss optic disc drusen (ODD, or pseudopapilledema) in the context of ...

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin. PulseSight Therapeutics SAS presented new data on its lead program PST-611, a DNA ...

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora. The Healthcare Private Equity team has advised Retina ...

"The De Novo authorization established Valeda as the first device for treatment of dry AMD patients with vision loss and creates a threshold for this novel class of photobiomodulation (PBM) devices ...

Ferhina S. Ali, MD, MPH, presenting at the OSN New York Retina meeting, discussed advances in next-generation anti-VEGF therapies, focusing on real-world data compared with clinical trial outcomes.

The US Food and Drug Administration (FDA) has granted the lead asset for FELIQS, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). According to a press release 1 ...

Vaidehi S. Dedania, MD, from the New York University (NYU) Langone Health and the Grossman School of Medicine, spoke with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. She ...

Dr. Mammo discussed this evolution and how to choose patients who would best benefit from GA therapy. Clinicians’ attitudes toward geography atrophy (GA) and treatment have been changing in the short ...